To eliminate HCV worldwide, HCV-infected patients with renal impairment should be treated with interferon-free therapies.Hepatology International
In the study, conducted at Weill Cornell Medical College in New York City, 15 patients with chronic HCV infection were treated with telaprevir-based triple therapy (consisting of telaprevir/pegylated interferon alfa/ribavirin), an HCV treatment regimen that was approved by the Food and Drug Administ...
Rituximab is a chimeric monoclonal antibody targeting CD20-expressing B cells. It has been commonly used as an off-label treatment for ITP for nearly 2 decades. The short-term response rates range from 60 to 70% in patients treated with the standard 4 weekly doses of 375 mg/m2rituximab, a...
Rituximab is a chimeric monoclonal antibody targeting CD20-expressing B cells. It has been commonly used as an off-label treatment for ITP for nearly 2 decades. The short-term response rates range from 60 to 70% in patients treated with the standard 4 weekly doses of 375 mg/m2 rituximab,...
of a response. If HCV is still detectable at that time, therapy should probably be stopped. If HCV RNA is no longer detectable, therapy can be stopped in those infected with HCV genotypes 2 and 3 while it should be continued for a full 12 months in those with the more common genotype ...
Whereas the diagnosis of HCV is confirmed by HCV RNA positivity, the diagnosis of AIH is less precise but centred on autoantibody positivity (ANA, SMA and/or anti-LKM1) and characteristic hepatic histological findings. Clarification of the diagnosis is important since chronic HCV is treated with ...
However, by 2022, in the WHO European Region only 29% of HCV infected individuals have been diagnosed and 9% of all infected have been treated, whereas 126,000 new HCV infections were reportedin that year [3]. According to a multiparametric evidence synthesis performed in European Union (EU...
(HCV) associated and regression of the MZL can be achieved with antiviral therapy; for this reason, we test patients with newly diagnosed SMZL for HCV prior to proceeding with treatment [141,142]. Our preference for frontline treatment is rituximab monotherapy, which is associated with a ...
Researchers hope that their discovery may in the long run lead to developing new, cheaper medicines that will enable all people infected with HCV to be treated. It is also critical to increase our understanding of the strategies viruses use to outwit us. The knowledge gained from this study ma...
We emulated a randomized trial to answer the question of whether easy to treat patients with genotype 1 HCV could be treated with sofosbuvir/ledipasvir (SOF/LDV) rather than sofosbuvir/velpatasvir (SOF/VEL). Patients without comorbidities or end stage liver disease were selected from the British...